BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Akums Drugs & Pharmaceuticals Ltd

Pharmaceuticals

Offer Period :

30th to 1st Aug 2024

Established in 2004, Akums is a leading pharmaceutical CDMO providing extensive services in India and abroad. Notable clients as of September 30, 2023, comprise Alembic Pharmaceuticals, Read more... Alkem Laboratories, Cipla, Dabur India, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and more.Read less

Akums Drugs & Pharmaceuticals Ltd IPO Details

IPO Date 30th to 1st Aug 2024 Minimum Investment ₹14938 / 1 Lots
Listing Date 2024-08-06 Maximum Investment ₹194194 / 13 Lots
Face Value ₹2 per share Total Issue Size ₹1856.74 Crores
Price ₹679 to ₹679 per share Fresh Issue ₹680 Crores
Lot Size 1 Lots (22 Shares) Offer For Sale ₹ 1176.74
Listing At BSE, NSE Retail Discount ₹ 0
Employee Discount ₹64 per share    
IPO Date 30th to 1st Aug 2024
Listing Date 2024-08-06
Face Value ₹2 per share
Price ₹679 to ₹679 per share
Lot Size 1 Lots (22 Shares)
Listing At BSE, NSE
Employee Discount ₹64 per share
Minimum Investment ₹14938 / 1 Lots
Maximum Investment ₹194194 / 13 Lots
Total Issue Size ₹1856.74 Crores
Fresh Issue ₹680 Crores
Offer For Sale
Retail Discount ₹ 0

Timeline

Important dates for allocation and IPO listing.

30th Jul

IPO Starts

1st Aug

IPO Ends

2nd Aug

Allotment Date

5th Aug

Initiation of Refund

5th Aug

Credit of Shares to Demat Account

6th Aug

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 82.44 0
Public Group 17.56 0

Akums Drugs & Pharmaceuticals Ltd IPO Reservation

QIB Shares Offered 20343188(74.39%)
NII (HNI) Shares Offered 4068637(14.88%)
Retail Shares Offered 2712425(9.92%)
Anchor Investor Shares Offered 0(0%)
Total Shares Offered 27345164
Total Shares With Anchor Investor 27345164

IPO Lot Size

ApplicationLotsSharesAmount
Retail (Min)---
Retail (Max)---
S-HNI (Min)---
S-HNI (Max)---

Akums Drugs & Pharmaceuticals Ltd IPO Registrar

Link Intime India Pvt Ltd
Phone Number +91 810 811 4949
Email Id akumsdrugs.ipo@linkintime.co.in
Our Website www.linkintime.co.in

Akums Drugs & Pharmaceuticals Ltd IPO Lead Manager

1. ICICI Securities Ltd

2. Axis Capital Ltd

3. Citigroup Global Markets India Pvt Ltd

4. Ambit Pvt Ltd

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Akums Drugs & Pharmaceuticals Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed

Strength of Akums Drugs & Pharmaceuticals Ltd

1. Largest India-focused CDMO serving the Indian domestic pharmaceutical industry.

2. Diverse client base with longstanding CDMO relationships.

3. Large and rapidly growing R&D capabilities across its product portfolio.

4. Strategic presence across the pharmaceutical value chain.

5. Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused PE investor.

Risks Involved

1. Its manufacturing units and research and development centres are concentrated in Haridwar, Uttarakhand and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

2. Any slowdown or shutdown in its manufacturing and research and development operations could have an adverse effect on its business, results of operations, financial condition and cash flows.

3. Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.

4. Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on the company's business, results of operations, financial condition and cash flows.

5. The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.

6. The Company had issued Equity Shares to more than 49 investors in the past, which may have been in non-compliance with the Companies Act, 1956.

7. The company import some of its raw materials from China and other countries and source its remaining raw materials domestically. Any delay, interruption or reduction in the supply of such raw materials could adversely affect its business, financial condition and results of operations.

8. Its success depends on the company's ability to successfully develop and commercialize new products in a timely manner. Any failures to do so could adversely affect its business, results of operations and financial condition.

9. Certain of its corporate records, filings and instruments of transfer are not traceable. Its cannot assure you that no legal proceedings or regulatory actions will be initiated against the company in the future in relation to any such discrepancies.

10. The company has incurred losses in the past and may incur losses in the future.

Why should you invest in

-

Financials

Particulars For the financial year ending (in ₹ million)
  2024 2023 2022
Total Assets 3516.36 3266.53 3069.05
Total Liabilities 3516.36 3266.53 3069.05
Total Expenses 4231.45 3519.89 3874.95
Total Revenue 
4212.21 3744.89 3694.52
Profit After Tax -4.03 94.86 -252.54
EBITDA 130.98 309.35 -81.86
Adjusted EBITDA 0 0 0

Akums Drugs & Pharmaceuticals Ltd IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
2024-08-06 544222 AKUMS
INE09XN01023
₹679 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹679 ₹679
Open ₹725 ₹725
Low ₹724.5 ₹725
High ₹797.45 ₹797.5
Low ₹724.5 ₹725

Frequently Asked Questions

What is Akums Drugs & Pharmaceuticals Ltd IPO?

Answer Field

Akums Drugs & Pharmaceuticals Ltd IPO is a Mainboard IPO of 2,73,45,164 equity shares of a face value of ₹2 aggregating up to ₹1856.74 Crores. The issue is priced at ₹679 to ₹679 per share. The minimum order quantity is 22 Shares. The IPO opens on July 30, 2024, and closes on August 01, 2024. Link Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Akums Drugs & Pharmaceuticals Ltd IPO will open?

Answer Field

The Akums Drugs & Pharmaceuticals Ltd IPO opens on July 30, 2024 and closes on August 01, 2024.

What is the lot size of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

Akums Drugs & Pharmaceuticals Ltd lot size is 22 shares, and the minimum amount required is ₹14,938.

How to apply for Akums Drugs & Pharmaceuticals Ltd IPO?

Answer Field

You can apply in Akums Drugs & Pharmaceuticals Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Akums Drugs & Pharmaceuticals Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Akums Drugs & Pharmaceuticals Ltd IPO will be done on August 02, 2024, and the allotted shares will be credited to your demat account by August 05, 2024.

When is Akums Drugs & Pharmaceuticals Ltd IPO listing date?

Answer Field

The Akums Drugs & Pharmaceuticals Ltd listing date is August 06, 2024.

Who is the registrar of Akums Drugs & Pharmaceuticals Ltd IPO?

Answer Field

The registrar of Akums Drugs & Pharmaceuticals Ltd IPO is Link Intime India Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

ICICI Securities Ltd,Axis Capital Ltd,Citigroup Global Markets India Pvt Ltd,Ambit Pvt Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Akums Drugs & Pharmaceuticals Ltd IPO?

Answer Field

The fresh issue size is ₹680 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Akums Drugs & Pharmaceuticals Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 22 shares and ₹14,938 amount.

How can I approve the UPI mandate request for Akums Drugs & Pharmaceuticals Ltd IPO?

Answer Field

To apply for Akums Drugs & Pharmaceuticals Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The price of each Akums Drugs & Pharmaceuticals Ltd share will be ranging in between ₹679 to ₹679 per share.

What is the cut-off time for the UPI mandate for Akums Drugs & Pharmaceuticals Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, August 01, 2024.

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • YASH HIGHVOLTAGE LIMITEDSME IPO

  • Bidding Dates

    12th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹138.0 - 146.0

  • IPO Size

    ₹1,10,01,00,000

  • Apply Now
  • HAMPS BIO LIMITEDSME IPO

  • Bidding Dates

    13th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹51.0 - 51.0

  • IPO Size

    ₹6,22,00,000

  • Apply Now
  • NACDAC INFRASTRUCTURE LIMITEDSME IPO Early Access

  • Bidding Dates

    17th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹33.0 - 35.0

  • IPO Size

    ₹10,01,00,000

  • Apply Now
  • NACDAC INFRASTRUCTURE LIMITEDSME IPO Early Access

  • Bidding Dates

    17th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹33.0 - 35.0

  • IPO Size

    ₹10,01,00,000

  • Apply Now
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • SWIGGY LIMITEDMainboard IPO

  • Bidding Dates

    6th Nov 2024 - 11th Nov 2024

  • Price Range

    ₹371.0 - 390.0

  • IPO Size

    ₹1,13,27,43,00,000

  • Invest Now
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)
  • Lorem Ipsum
  • ONYX BIOTEC LIMITEDSME IPO

  • Issue Price

    61.00

  • Listing Day Close

    56.75

  • Listing Day (Gain/Loss)

    -6.56

  • SWIGGY LIMITEDMainboard IPO

  • Issue Price

    390.00

  • Listing Day Close

    455.95

  • Listing Day (Gain/Loss)

    16.92

  • DANISH POWER LIMITEDSME IPO

  • Issue Price

    380.00

  • Listing Day Close

    598.50

  • Listing Day (Gain/Loss)

    57.63

We have something for everyone

Explore more Investment options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text